Business context and reporting period
QT Imaging Holdings, Inc. filed this Form 10-K for the fiscal year ended December 31, 2023, when it was still GigCapital5, Inc., a special purpose acquisition company (SPAC) with no operating business or revenue. It completed its merger with QT Imaging, Inc. on March 4, 2024, and changed its name to QT Imaging Holdings, Inc. The audited 2023 financial statements therefore reflect the SPAC, not the post-merger medical-device company.
QT Imaging develops and commercializes low-energy-sound body imaging systems. Its QT Breast Scanner is FDA-cleared for breast imaging, but the filing states it is not intended to replace screening mammography. The company describes additional applications and products as development or longer-term opportunities.
Financial results and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.93 million | $4.28 million |
| Net loss | $4.02 million | $2.77 million |
| Cash used in operating activities | $1.94 million | $1.26 million |
| Cash outside trust at year-end | $2,438 | $78,196 |
| Cash in trust at year-end | $23.30 million | $41.56 million |
Interest income on trust assets was $1.53 million in 2023, versus $1.63 million in 2022. The 2023 net loss also included $219,686 of interest expense and a $419,119 income-tax provision. The SPAC had no operating revenue, so operating margins are not meaningful.
At December 31, 2023, total liabilities were $12.69 million, including $1.56 million on the extension note, a $1.51 million fair-value carrying amount for the related-party convertible working-capital note, $3.50 million of accrued legal fees, and $2.76 million of current deferred underwriting fees. Redeemable common stock of $23.22 million was presented outside stockholders’ deficit. The balance sheet reported a stockholders’ deficit of $12.51 million. No long-term debt or lease obligations were reported.
The SPAC had $2,438 of unrestricted cash at year-end and relied on sponsor loans and trust funds to meet obligations. It recorded a $4.02 million loss and used $1.94 million in operating cash during 2023. The filing states that these conditions raised substantial doubt about the SPAC’s ability to continue as a going concern. After the merger, the combined company received approximately $826,420 from the trust account, $9.005 million net from a Yorkville prepaid advance, and $1.5 million from a note payable. Management stated that these funds and financing arrangements were expected to cover operating needs for at least 12 months from the financial-statement issuance date.
Separately, the filing cites QT Imaging’s pre-merger losses of approximately $6.1 million in 2023 and $6.3 million in 2022, operating cash use of $2.7 million and $3.9 million, respectively, and year-end 2023 working-capital deficit of $2.5 million, compared with working capital of $4.1 million in 2022. These figures are distinct from the audited SPAC financial statements summarized above.
Material changes and significant transactions
- SPAC net loss increased by about $1.25 million year over year, while operating cash use increased by about $0.68 million.
- Trust assets fell from $41.56 million to $23.30 million, principally amid public-share redemptions. Redemptions included approximately $192.1 million in 2022 and further withdrawals in 2023; additional redemptions occurred after year-end.
- Wells Fargo waived $6.44 million of deferred underwriting fees in March 2023; $2.76 million of deferred underwriting fees remained current at year-end.
- Through the extensions, the sponsor advanced $1.56 million under the extension note and $1.50 million under a convertible working-capital note. At merger closing, $943,640 of the working-capital note converted into 94,364 shares and 94,364 warrants; the remaining $556,360 was repaid.
- The merger financing included a Yorkville facility allowing up to $50 million of stock purchases over 36 months. The $10 million prepaid advance carries 6% annual interest, rising to 18% upon default, and is convertible into common stock. A separate $1.5 million Funicular note is non-interest-bearing, due 13 months after issuance, potentially convertible at $2 per share, and secured by certain assets, excluding intellectual property.
Outlook, commentary, and principal risks
Management expects continued losses and states that profitability depends on commercial adoption, manufacturing at viable cost and scale, regulatory progress, and sufficient reimbursement or customer demand. No quantified revenue or earnings guidance is provided. The company may need additional capital; equity financing could dilute shareholders, and debt may impose restrictive covenants.
- The QT Breast Scanner has limited deployment and the company has not demonstrated manufacturing and commercial deployment at scale. FDA clearance is for specified breast-imaging uses, not as a replacement for screening mammography; expanded screening use would require further regulatory review.
- Market acceptance, clinical evidence, reimbursement, scan utilization, sales capacity, and the viability of the proposed scan-as-a-service model remain uncertain. The company says it has not established a target price per scan and had not discussed coding, coverage, or reimbursement with third-party payors.
- The company expects reliance on third-party suppliers and manufacturers but reports limited experience with large-scale manufacturing agreements. Supply interruptions, quality issues, or higher costs could delay commercialization.
- Other material risks include competition, additional regulatory requirements, intellectual-property challenges, product liability, cybersecurity and health-data privacy, and difficulty recruiting and retaining key staff.
- The filing reports no material legal proceedings as of December 31, 2023. The SPAC auditor issued an unqualified opinion on its financial statements; the auditor did not audit internal-control effectiveness. Management reported effective disclosure controls and internal control over financial reporting for the SPAC as of year-end.
Important facts for investors to verify
- Post-merger cash, current burn rate, debt maturities, covenant compliance, and whether management’s stated 12-month liquidity expectation remains supportable.
- Actual proceeds and terms of Yorkville and other financing, including conversion mechanics, share issuance, security interests, and any further advances.
- Current share count, potential dilution from warrants, equity awards, registration rights, earnout shares, and the Yorkville equity facility.
- QT Imaging’s audited operating results, cash flows, working capital, revenue, and gross-margin performance, separately from the SPAC’s 2023 results.
- Number of scanners deployed, sales and scan utilization, manufacturing capacity and costs, clinical evidence, regulatory submissions, and reimbursement progress.